Active Pulmonary Tuberculosis Management

Standard Treatment Regimen for Drug-Susceptible TB

• The American College of Chest Physicians recommends a 6-month regimen for active pulmonary tuberculosis, consisting of an initial intensive phase of 2 months with four drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) given daily, followed by a continuation phase of 4 months with isoniazid and rifampin given daily 1
• The standard 6-month duration applies to patients with non-cavitary disease who have negative sputum cultures at 2 months 1

Extended Treatment Indications

• Extend the continuation phase to 7 months (total 9 months of treatment) if cavitary disease is present on initial chest radiograph, or if sputum cultures remain positive at completion of 2 months of treatment 1

Critical Monitoring Requirements

Bacteriologic Monitoring

• Obtain sputum cultures monthly until two consecutive negative cultures are documented 1
• Patients should demonstrate sputum conversion (culture negativity) within 3 months of treatment initiation 1
• If sputum remains smear-positive at 3 months, immediately evaluate for non-adherence, treatment failure, or drug resistance 1

Drug Susceptibility Testing

• Obtain drug susceptibility testing on all initial isolates before starting treatment to confirm susceptibility to at least isoniazid, rifampin, pyrazinamide, and ethambutol 1

Treatment of Multidrug-Resistant TB (MDR-TB)

• For MDR-TB (resistance to at least isoniazid AND rifampin), use the 6-month BPaLM regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin for eligible patients 1
• Use at least 5 drugs in the intensive phase and at least 4 drugs in the continuation phase when using traditional longer MDR-TB regimens 2

Treatment of Recurrent TB

• Assume acquired drug resistance in all recurrent TB cases until proven otherwise, and initiate treatment with at least 4 drugs including a fluoroquinolone based on prior treatment history 1
• Obtain drug susceptibility testing immediately before initiating treatment, including testing for resistance to isoniazid, rifampin, pyrazinamide, and fluoroquinolones 1

Special Populations

HIV-Infected Patients

• Use the same standard 6-month regimen, but consider extending treatment to at least 9 months and at least 6 months after documented culture conversion 3
• Screen antimycobacterial drug levels in patients with advanced HIV disease to prevent malabsorption and emergence of resistance 2

Common Pitfalls to Avoid

• Do not treat recurrent TB with the same regimen that failed previously—this guarantees further resistance 1
• Do not rely on clinical improvement alone—bacteriologic confirmation of cure is essential 1
• Monitor for hepatotoxicity with baseline and regular liver function tests, especially in patients with chronic liver disease 3
• Adjust doses of oral hypoglycemics in diabetic patients, as rifampin reduces sulfonylurea efficacy 3

Standard 6‑Month Regimen for Drug‑Susceptible Pulmonary Tuberculosis

Regimen Composition and Phases

• The recommended treatment consists of a 2‑month intensive phase with daily isoniazid, rifampin, pyrazinamide, and ethambutol administered seven days per week for a total of 56 doses; ethambutol may be stopped once susceptibility to isoniazid and rifampin is confirmed【4】.
• The continuation phase follows for 4 months with daily isoniazid plus rifampin given seven days per week for 126 doses【4】.

Dosing Recommendations (Adults)

• Isoniazid 5 mg/kg (≈300 mg daily)【4】.
• Rifampin 10 mg/kg (≈600 mg daily)【4】.
• Pyrazinamide 15–30 mg/kg daily【4】.
• Ethambutol 15–25 mg/kg daily; higher doses may improve efficacy but increase risk of ocular toxicity【4】.

Treatment Duration Adjustments

• Extend the total treatment to 9 months (i.e., a 7‑month continuation phase) when any of the following are present: cavitary disease on the initial chest radiograph or sputum cultures remain positive after the 2‑month intensive phase【4】.

Monitoring and Adherence Strategies

• Obtain sputum cultures monthly until two consecutive negative results are documented; sputum conversion should occur within 3 months of therapy initiation【4】.
• If sputum remains smear‑positive at 3 months, promptly assess for non‑adherence, treatment failure, or drug resistance【4】.
• Perform drug‑susceptibility testing on all initial isolates before starting therapy to confirm susceptibility to isoniazid, rifampin, pyrazinamide, and ethambutol【4】.
• Directly observed therapy (DOT) is recommended to ensure treatment completion and to prevent the emergence of resistance【4】.

Special Considerations

• In patients with severe liver disease, pyrazinamide should be omitted; the regimen then consists of 2 months of isoniazid, rifampin, and ethambutol daily, followed by a 7‑month continuation phase (total 9 months)【4】.
• Pregnancy is an absolute contraindication to shortened multidrug‑resistant TB regimens, although shortened regimens are not recommended for drug‑susceptible TB【5】【6】.

Shortened Regimens for Multidrug‑Resistant TB (Not Applicable to Drug‑Susceptible TB)

• Shortened (9–12 month) all‑oral regimens are reserved exclusively for confirmed MDR/RR‑TB; they are not indicated for drug‑susceptible disease【7】【8】.
• The MDR/RR‑TB regimen includes an intensive phase of 4–6 months with bedaquiline, a fluoroquinolone (levofloxacin or moxifloxacin), ethionamide, clofazimine, pyrazinamide, high‑dose isoniazid, and ethambutol, followed by a 5‑month continuation phase with fluoroquinolone, clofazimine, ethambutol, and pyrazinamide【7】【8】.
• Eligibility for this regimen requires confirmed MDR/RR‑TB, exclusion of fluoroquinolone resistance, absence of extensive disease, and no prior exposure to second‑line drugs for more than one month【7】【8】【6】.